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A hallmark of B-cell immunity is the generation of a diverse re-
pertoire of antibodies from a limited set of germline V(D)J genes.
This repertoire is usually defined in terms of amino acid compo-
sition. However, variable domains may also acquire N-linked gly-
cans, a process conditional on the introduction of consensus amino
acid motifs (N-glycosylation sites) during somatic hypermutation.
High levels of variable domain glycans have been associated with
autoantibodies in rheumatoid arthritis, as well as certain follicular
lymphomas. However, the role of these glycans in the humoral
immune response remains poorly understood. Interestingly, stud-
ies have reported both positive and negative effects on antibody
affinity. Our aim was to elucidate the role of variable domain
glycans during antigen-specific antibody responses. By analyzing
B-cell repertoires by next-generation sequencing, we demonstrate
that N-glycosylation sites are introduced at positions in which gly-
cans can affect antigen binding as a result of a specific clustering
of progenitor glycosylation sites in the germline sequences of vari-
able domain genes. By analyzing multiple human monoclonal and
polyclonal (auto)antibody responses, we subsequently show that
this process is subject to selection during antigen-specific antibody
responses, skewed toward IgG4, and positively contributes to
antigen binding. Together, these results highlight a physiological
role for variable domain glycosylation as an additional layer of anti-
body diversification that modulates antigen binding.
antibody diversification | variable domain glycosylation | Fab glycosylation
Immunoglobulins are glycoproteins produced by plasma cellsthat are crucial for protective immunity. The most abundant
class of immunoglobulins in the blood is IgG, representing 75%
of total serum immunoglobulins. All IgGs contain glycans that
are linked to a conserved asparagine in the constant Fc tail. These
glycans have a profound effect on IgG effector functions by af-
fecting FcR and C1q binding (1, 2), underscored by the fact that
therapeutic monoclonal antibodies with enhanced cytotoxic po-
tency have been developed by glycoengineering of these Fc glycans
(3). In addition, about 15% of IgGs in serum from healthy humans
have been described to contain N-linked glycans in the variable
domains of the Fab arms (4). These mainly consist of complex
biantennary glycans that contain high percentages of sialic acid in
comparison with Fc glycans (4–7).
The role of these Fab glycans in immunity is poorly un-
derstood. Notably, enhanced Fab glycosylation is associated with
certain pathophysiological conditions, including rheumatoid ar-
thritis (RA) (8), primary Sjögren’s syndrome (9), and several
types of malignancies (10–13). Nevertheless, the role of Fab
glycosylation in pathogenesis has not been established for any of
these conditions. In contrast to these studies, Fab glycans have
also been implicated as contributing to the anti-inflammatory
activity of i.v. Ig (IVIg) (14) or reducing autoimmunity by mask-
ing antigen-binding sites of autoantibodies (15). Also, elevated Fab
glycosylation was reported during pregnancy (5). In addition, Fab
glycans have been implicated to affect antigen binding (16–20).
Importantly, a coherent model of the emergence and functional
consequences of Fab glycosylation is currently lacking. Insight
into the events leading to Fab glycosylation would be a pre-
requisite to a more detailed understanding of the role of Fab
glycans in pathogenicity and immunity in general.
N-linked glycosylation is contingent on the presence of glyco-
sylation sites, which consist of asparagine, followed by any amino
acid but proline, followed by serine or threonine. The naive hu-
man B-cell antibody repertoire is almost devoid of such sites, with
only few variable domain alleles containing N-glycosylation sites
(7). The occurrence of Fab glycans in vivo is therefore expected to
mainly result from somatic hypermutation (SHM) during antigen-
specific immune responses (21). This implies that acquiring
N-linked glycans might be subject to selection mechanisms responsible
for affinity maturation. In this study, we demonstrate by next-
generation sequencing that SHM preferentially introduces N-
glycosylation sites in the complementarity determining regions
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(CDRs). Strikingly, this preference is largely predetermined by
precursor nucleotide motifs found in the germline variable domain
genes. Furthermore, we reveal that variable domain glycosylation
is subject to selection mechanisms that depend on the nature of
the antigen, resulting in significant antigen-associated selection,
and show that these glycans contribute directly to antigen binding,
and thereby to specificity. Collectively, our data show that variable
domain glycosylation is an inherent mechanism of antibody di-
versification, subject to selection mechanisms, on top of V(D)J
recombination and SHM, and thereby contributes to the extent of
the antibody repertoire of B cells.
Results
Fab Glycosylation Sites Preferentially Emerge Near Antigen-Binding
Regions. Antibody variable domains contain three hypervariable
regions, which coincide with three of the four structural loops at
the top of the variable domain (Fig. 1A). The large structural
diversity reflects the importance of these loops for conferring
specificity and binding to each unique antigen in the very large
antigen repertoire. We investigated whether glycans are prefer-
entially introduced in or near these regions, forming an additional
layer of diversification of the antibody repertoire. Therefore, as a
first approximation, the human germline VH, Vκ, and Vλ se-
quences were analyzed for positions in which a single nucleotide
mutation would suffice to introduce a glycosylation site (hereafter
referred to as a progenitor glycosylation site; see Fig. 1B as an
example). Interestingly, these positions were significantly clustered
around the CDRs and the loop between the second and third
CDR (the DE loop; Fig. 1C and SI Appendix, Fig. S1B), whereas
analysis of the human germline CH, Cκ, and Cλ sequences did not
show a similarly skewed distribution of progenitor glycosylation
sites (SI Appendix, Fig. S1 A and B), suggesting the germline
variable domain repertoire may contain a predefined set of loca-
tions in which glycosylation sites may be easily introduced on SHM.
We next extended our analysis to the mouse germline repertoire. A
similar, albeit less pronounced, clustering around the CDRs and
the DE loop was observed for progenitor glycosylation sites in the
variable domain sequences (SI Appendix, Fig. S2 A and C), whereas
no apparent clustering was observed for the constant domain se-
quences (SI Appendix, Fig. S2 B and C).
Next, human rearranged VH sequences from the IMGT da-
tabase (Fig. 1D) and from switched memory B cells isolated from
seven healthy donors (Fig. 1E) were analyzed for the actual oc-
currence of N-glycosylation sites. This uncovered a distinct pattern
in the distribution of Fab glycosylation sites in both datasets, with
most sites being located either in or near the CDRs or the DE
loop, such that an attached glycan has the potential to influence
the binding properties of the antibody. In addition, within the
IGHV genes, the majority of the sites (respectively, 79% and 86%)
are in fact the actualization of a progenitor glycosylation site (i.e.,
are the result of a single nucleotide mutation). This distribution of
Fab glycosylation sites was similar between IgG and IgA sequences
(SI Appendix, Fig. S1 C and D), whereas frequencies of individual
sites can vary substantially between donors (SI Appendix, Fig. S1E).
This demonstrates that a predefined progenitor glycan repertoire
is the predominant source of glycosylation sites after SHM in
memory B cells. These observations were extended to patients with
systemic lupus erythematosus and mouse rearranged VH sequences
of IgG-switched B cells (22) (SI Appendix, Figs. S3 and S2D), with
87% and 79% of sites matching progenitor sites. Sequences with a
glycosylation site contained more replacement mutations than
sequences without a glycosylation site, and sequences with two
glycosylation sites contained even more mutations (SI Appendix,
Fig. S4), in agreement with SHM being responsible for introducing
these sites. Overall, almost 9% of all human rearranged VH sequences
were demonstrated to contain one or more sites, versus 4.4%
for mouse, which is in line with the lower overall mutation rate
in mouse (SI Appendix, Fig. S4) (23). Glycosylation sites are
less frequent in IGHV3 (5%) than IGHV4 (19%), with IGHV1
intermediate between those (9%), a frequency similar to a pre-
vious report (15). Together, these data show that Fab glycosylation
sites preferentially emerge near antigen-binding regions, and that
the germline variable domain repertoire is inherently biased to-
ward this distribution. NXS sequons were three times as common
as NXT (SI Appendix, Fig. S5A). NXS sequons tend to be less
frequently glycosylated (24), depending on, among other factors,
the amino acid at position X. The most frequent amino acid at
position X was leucine, associated with low glycosylation effi-
ciency, but the next four most frequent amino acids predispose for
more efficient glycosylation (SI Appendix, Fig. S5 A and B) (25).
Of note, in sequons within the CDR3, the frequency of leucine at
position X was low (SI Appendix, Fig. S5C). Furthermore, the in-
troduction of a glycosylation site in a model antibody, adalimumab,




Fig. 1. Fab glycosylation sites preferentially emerge near antigen-binding
regions. (A) Both variable domains (VH, VL) of an antibody Fab arm contain
four top loops: three complementarity determining regions (CDR1, CDR2,
CDR3, red), which usually constitute the antigen-binding site, and the ad-
jacent DE loop (blue). (B and C) Triplets of codons were screened for the
possibility of coding for a glycosylation site on mutating a single nucleotide
anywhere within the triplet of codons, of which an example is shown in B
(see Materials and Methods for details). (C) Heat map of positions in which
progenitor glycosylation sites are located within human germline VH, Vκ, and
Vλ sequences (Dataset S1, only *01 alleles shown). A darker shade indicates
multiple possibilities for a single nucleotide mutation to introduce a glyco-
sylation site at that position. Numbering according to IMGT. (D and E)
Number of N-glycosylation sites at different positions within human rear-
ranged VH sequences from (D) the IMGT database (4,026 unique sequences)
and (E) switched memory B cells from seven healthy donors (37,077 unique,
productive sequences out of a total of 82,281). Dark green bars represent
sites that match predicted progenitor sites (C). Bars below the X axis rep-
resent germline glycosylation sites, and dark shades represent those sites
that are not removed by mutations. (F) Eight variants of adalimumab (SI
Appendix, Table S1) were expressed with a glycosylation site introduced at
one of the indicated positions in the crystal structure of adalimumab Fab
(PDB ID: 3WD5). The position of the Fab glycan is indicated (e.g., NH59 indicates
a Fab glycan at position 59 of the heavy chain). (G) Gel electrophoresis and
lectin ELISA data for the eight adalimumab glycovariants. WGA recognizes N-
acetylglucosamine, RCA recognizes galactose, and SNA recognizes sialic acid.
Shown are representative data of two replicates.
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that for seven of eight positions, the sites indeed became occupied
with glycans (including all five NXS sites), as confirmed by gel
electrophoresis and lectin ELISAs (Fig. 1 F andG and SI Appendix,
Table S1). In other words, the introduction of glycosylation sites at
predicted positions in general results in properly folded antibodies
that express glycans in the variable domains.
Fab Glycosylation Differs Between IgG Subclasses and Specificities.
Next, we investigated whether Fab glycosylation is subject to
(context-dependent) selection mechanisms during specific anti-
body responses. We first analyzed whether there were distinct
levels of Fab glycosylation between IgG subclasses. To this end,
we fractionated eight healthy donor sera using Sambucus nigra
agglutinin (SNA) affinity chromatography (Fig. 2A), making use
of the fact that SNA enriches for Fab glycans, but not for Fc
glycans (14, 26, 27) (SI Appendix, Fig. S6), through their terminal
2,6-linked sialic acid residues found in >90% of Fab glycans (5).
A median of 11% [interquartile range (IQR), 11–14%] of total
serum IgG was found to contain sialylated Fab glycans (i.e., was
recovered in the enriched fraction), as measured by ELISA.
Interestingly, by the same method, IgG4 Fab glycosylation (44%;
IQR, 39–49%) was found to be significantly increased compared
with that of total IgG, whereas Fab glycosylation of IgG1 (12%;
IQR, 11–18%), IgG2 (11%; IQR, 9.6–16%), and IgG3 (15%;
IQR, 11–16%) was not (Fig. 2B). This result can partially be
explained by the ability of IgG4 antibodies to engage in Fab-arm
exchange, resulting in an increased fraction of IgG4 antibodies
that carry at least one glycan (Fig. 2C). However, by mathe-
matically accounting for the Fab-arm exchange (for calculations
see Materials and Methods), 25% (IQR, 22–28%) of IgG4 was
calculated to contain Fab glycans, indicating that the IgG4 BCR
repertoire itself is also intrinsically biased toward increased Fab
glycosylation. This observation was corroborated by analysis of human
rearranged IgG4 VH sequences of healthy volunteers (28), of
which 30% (87/288) contained a glycosylation site compared
with 13% (264/2,063) for IgG1 reads (SI Appendix, Fig. S14).
We next analyzed whether there were distinct levels of Fab
glycosylation between antibodies specific for different antigens.
For a typical IgG4-dominated immune response, namely, expe-
rienced (healthy) beekeepers that make antibodies to phospho-
lipase A2 (PLA2) in bee venom (29), we found that levels of Fab
glycosylation of anti-PLA2 IgG (of which a median of 66% was
IgG4) were similar to those of total IgG4, but significantly ele-
vated compared with those of total IgG (41% vs. 44% vs. 12%;
Fig. 2D). Also, Fab glycosylation levels of anti-PLA2 IgG4 were
similar to those of total IgG4 (SI Appendix, Fig. S7A). In con-
trast, antibodies to tetanus toxoid (TT), a typical vaccine antigen
that mainly induces IgG1, had levels of Fab glycosylation com-
parable to those of total IgG (13%). To extend these findings, we
also investigated sera from patients who make antibodies to
adalimumab or infliximab in response to treatment with these
biologicals [of which a substantial fraction is IgG4 (30, 31), a
median of 44% and 32% in the samples tested]. Again, we found
high levels of Fab glycosylation for anti-adalimumab (47%; Fig.
2E) and anti-infliximab (53%; Fig. 2F). However, in both cases,
Fab glycosylation was in fact significantly higher than that of
total IgG4 (which again was elevated compared with total IgG;
Fig. 2 E and F), indicating an increased positive selection for Fab
glycosylation compared with a typical IgG4-dominated immune
response. This was confirmed by measuring glycosylation levels
of anti-adalimumab IgG4 and anti-infliximab IgG4, which were
increased compared with those of total IgG4 (SI Appendix, Fig.
S7 B and C). We obtained similar results using the percentage of
Fab glycosylation of specific IgG and total IgG4 corrected for
IgG4 half-molecule exchange (SI Appendix, Fig. S8). In contrast,
the antibody response to another biological, natalizumab, is
characterized by low levels of IgG4 (median, 4%), and lower
levels of Fab glycosylation were observed by analyzing serum
samples from natalizumab-treated patients with multiple sclerosis
(26%; Fig. 2G), which were still significantly higher compared with
total IgG, but not compared with anti-TT. Furthermore, multiple
additional antigen-specific responses were evaluated. We also an-
alyzed sera from patients with RA containing anticitrullinated
protein antibodies (ACPAs), and observed a median of 89% Fab
glycosylation, in line with the recently reported high degree of Fab
glycosylation of these autoantibodies (32) (Fig. 2H). Interestingly,
for another inflammation-associated antibody response, namely,
anti-hinge antibodies (33), our data also show increased Fab glyco-
sylation (53%; Fig. 2I). In contrast, Fab glycosylation of antibodies
against the RhD blood group antigen was found to be decreased
in pooled serum IgG of RhD-immunized donors compared with
A B C
D E F




Fig. 2. Fab glycosylation differs between IgG subclasses and specificities.
(A) SNA affinity chromatography of IgG results in SA+ IgG (enriched for Fab
glycosylated IgG) and SA− IgG (almost devoid of Fab glycosylated IgG) (4, 24,
27, 28) (SI Appendix, Fig. S6). Total and specific IgG is measured in both
fractions by ELISA, RIA, or agglutination (Materials and Methods). (B) Per-
centage of Fab glycosylated antibodies (Abs) for total IgG and IgG subclasses
in healthy donor sera (n = 8). Symbols represent means of at least six replicates. ♦,
before, and ♢, after correction for IgG4 half-molecule exchange. (C) IgG4 mol-
ecules can exchange half-molecules, resulting in a fraction of IgG4 molecules
carrying a Fab glycan on only one of the two Fab arms. (D–J) Percentage of Fab
glycosylated Abs for total (T) IgG/IgG4, anti-tetanus toxoid (TT), and (D) anti-
PLA2 [in sera from experienced beekeepers, n = 10, of which 66% (58–86%) is
IgG4], (E) anti-adalimumab [ADL; n = 11, of which 44% (14–97%) is IgG4], (F)
anti-infliximab [IFX; n = 9, of which 32% (20–73%) is IgG4], (G) anti-natalizumab
(NTZ; n = 10, E–G in sera from patients with a respective anti-biological antibody
response), (H) anti-cyclic citrullinated peptide (CCP; in sera from patients with
RA, n = 6), (I) anti-hinge (in sera from random subjects, n = 10), and (J) anti-RhD
(in pooled, fractionated plasma preparations of RhD-immunized donors, n = 3).
Symbols represent means of at least four replicates. Bars indicate medians.
One-way ANOVA, *P < 0.05; **P < 0.01; ***P < 0.001; and ****P < 0.0001 or
paired t test, *P < 0.05; **P < 0.01. (K–M) Single B cells specific for ADL, IFX, or
RhD from patients who made anti-ADL or anti-IFX antibodies or from RhD-
immunized donors. (K ) Distribution of IgG1 and IgG4 among monoclonal
anti-ADL (n = 16) and anti-IFX (n = 8) antibodies. (L) Absence (0) or pres-
ence of glycosylation sites in the heavy (H) or light (L) chain or in both (H + L)
chains of monoclonal anti-ADL, anti-IFX, and anti-RhD (n = 294) antibodies.
(M) Number of N-glycosylation sites at different positions within human
rearranged VH sequences from monoclonal anti-ADL, anti-IFX, and anti-RhD
antibodies.





















that of total IgG or anti-TT (Fig. 2J). Together, these data dem-
onstrate that sialylated Fab glycans are differentially expressed in
a variety of immune responses, ranging from as low as 9.0% for
anti-RhD antibodies to more than 80% for ACPAs compared with
approximately 14% for anti-TT (median, 56 serum samples).
To confirm our findings at the DNA/monoclonal level, single
B cells specific for adalimumab or infliximab were isolated from
patients, cultured, and screened for specificity (34, 35). The
original isotypes were either IgG1 or IgG4, both approximately
50% (Fig. 2K). We found that 50% of the anti-adalimumab and
anti-infliximab B-cell clones contained Fab glycosylation sites
(Fig. 2L), in close agreement to the 47% and 53% Fab glyco-
sylation of serum-derived anti-adalimumab and anti-infliximab
antibodies, respectively (Fig. 2 E and F). We confirmed that, of
the examined clones (7/8 anti-adalimumab and 4/4 anti-infliximab),
all glycosylation sites were occupied by glycans when expressed
recombinantly as IgG antibodies (SI Appendix, Tables S2 and S3).
We also analyzed variable domain sequences of B cells specific for
RhD obtained from hyperimmunized anti-D donors by the same
method. Analysis of these anti-RhD sequences showed a low fre-
quency of glycosylation sites (5.8%; Fig. 2L), consistent with the
low degree of glycosylation of pooled plasma-derived anti-RhD
antibodies (Fig. 2J). In all but one case, the sites in these antigen-
specific antibodies correspond to a predicted predefined site, and
they are located in or near the CDRs or the DE loop (Fig. 2M).
Taken together, we found different levels of Fab glycosylation
between specific IgG subsets (subclasses and specificities), indicating
that Fab glycosylation is not a random process but is, rather, subject
to context-dependent selection mechanisms (e.g., antigen binding)
during specific antibody responses.
Modulation of Antigen Binding by Fab Glycans. Next, we systemat-
ically investigated the effects of Fab glycosylation on antigen
binding. We started by evaluating the effects of Fab glycans that
were introduced at predicted predisposed sites in adalimumab
(Fig. 1F). For five of seven adalimumab glycovariants (NH59,
NH77, NH82, NH84, and NL37), binding to its antigen (TNFα)
was reduced to various degrees, as measured by competition
ELISA (Fig. 3 A–C). Unexpectedly, one of the other two gly-
covariants (NL86) showed a slightly enhanced TNFα binding. For
three variants, reduced binding to TNFα was (at least partially)
mediated by the glycans rather than the amino acid difference, as
demonstrated by the significantly less reduced binding of the same
clones expressed in the presence of tunicamycin, which blocks N-
linked glycosylation (Fig. 3C and SI Appendix, Fig. S9A). Thus, in-
troducing Fab glycans at predicted sites may affect antigen binding,
which in this model system in which no selection mechanisms are
operative is expected to predominantly result in decreased binding
strength, in line with our observations. We also investigated TNFα
binding by surface plasmon resonance (SPR). Although overall
similar results were obtained in comparison with the ELISA data,
clear differences compared with the inhibition ELISA were found
for two clones (NH77 and NL86; Fig. 3D), indicating that antigen
binding can be differentially influenced by Fab glycans, depending
on the context in which antigen is presented (i.e., free vs. bound to
another protein/antibody).
To further examine the modulating capacity of Fab glycans for
differential binding to related antigens, we determined how the
Fab glycans on the different adalimumab variants affect binding
to a panel of anti-adalimumab anti-idiotype antibodies. Here, the
anti-idiotype antibodies serve as surrogate antigens of adalimu-
mab, each having a slightly different mode of binding (34, 36)
(Fig. 3E). Overall, the adalimumab glycovariants that bound TNFα
with lower affinity also showed less binding of these anti-idiotype
antibodies (Fig. 3F and SI Appendix, Fig. S9B). However, the gly-
cans on adalimumab glycovariants NH59, NH82, NL37, and NL86
had substantial differential effects on the binding to these surrogate
antigens (Fig. 3F). For instance, although the glycan on variant
NH59 left binding to clone 27E1 fully unaffected, this glycan de-
creased binding to clone 6A10 more than 100 times. Similarly, the
glycan on variant NH82 decreased binding to clone 1.2 only two
times, whereas this glycan decreased binding to clone 2.10 more
than 20 times. This demonstrates that the introduction of a glycan
can selectively and differentially influence binding of an antibody
(in this case adalimumab) toward a panel of antigens (in this case
the anti-idiotype antibodies), suggesting a potential to modulate
the specificity of the antibody.
Naturally Occurring Fab Glycans Can Enhance Antigen Binding. We
also investigated the consequences of naturally occurring Fab gly-
cosylation for antigen binding. We tested antigen binding of several
of the anti-adalimumab and anti-infliximab antibody clones with
Fab glycosylation sites and mutants in which we removed these
naturally occurring Fab glycosylation sites by mutating these sites
back to germline (SI Appendix, Table S2). We confirmed the re-
moval of glycans by gel electrophoresis and lectin ELISAs (Fig. 4 A
and B). We then examined binding of the anti-adalimumab and
anti-infliximab antibodies with and without Fab glycans to their
respective antigens (adalimumab and infliximab) by SPR (Fig. 4C).
Three of seven tested clones (anti-adalimumab 2.2 and 2.6 and
anti-infliximab 1.3) showed no effect of these Fab glycans on an-
tigen binding (Fig. 4 D and E). In contrast, for anti-adalimumab
clone 1.3 and anti-infliximab clones 1.4 and 2.1, the presence of
Fab glycans resulted in up to a twofold higher affinity (Fig. 4 D and
E), suggesting that the B cells carrying BCRs with these Fab gly-
cans were positively selected during affinity maturation. Tunica-
mycin controls confirmed that the glycans, and not the change in
amino acid sequence, caused the increase in affinity (Fig. 4D and E).




Fig. 3. Fab glycans can modulate antigen binding. (A) Setup of the TNF
inhibition ELISA for assessing relative (rel) binding strengths of adalimumab
(ADL) glycovariants to TNF. (B) TNF binding by in-house expressed ADL (WT),
ADL glycovariants (+Fab glycan, black bars, notation as in Fig. 1F), and these
variants expressed in the presence of tunicamycin or depleted using SNA
(−Fab glycan, gray bars) was determined. Humira (ADL) and Mabthera (rit-
uximab) were used as positive and negative controls. (C) Inhibitory potency
relative to WT (means of at least four replicates with SEM). (D) TNF binding
by ADL WT and glycovariants (+/−Fab glycan) determined by biosensor (SPR)
experiments. Affinity relative to WT (means of at least four replicates with
SEM). (E) Setup of the ADL-anti-ADL competition ELISA. (F) Binding of ADL
glycovariants NH59, NH82, NL37, and NL86 (+/−Fab glycan) to the anti-ADL
clones was determined as inhibitory potency relative to WT (means of at
least four replicates with SEM). Unpaired t test, legend as in Fig. 2.
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(N84K), suggesting the glycan on this clone may be important for
its stability. However, tiny amounts of this clone were expressed in
the presence of tunicamycin, and a nearly twofold higher affinity was
found for the glycosylated variant (Fig. 4E). For anti-adalimumab
1.3, the influence of sialylation was investigated, suggesting a modest
contribution to affinity (SI Appendix, Fig. S10). Taken together,
these results demonstrate that Fab glycosylation can enhance affinity
of antibodies toward their cognate antigens.
Discussion
Although it has been known for quite some time that glycans can
be present on the variable domains of antibodies, the precise
function of these Fab glycans remains poorly understood. Here,
we present three important findings. First, Fab glycosylation sites
preferentially emerge near antigen-binding regions because of an
inherent bias in the germline variable domain repertoire. Sec-
ond, different levels of Fab glycosylation exist between IgG
subclasses and specificities, demonstrating that Fab glycosylation
is not a random process but, rather, is subject to (antigen-asso-
ciated) positive and/or negative selection mechanisms. Third, we
found that Fab glycans can modulate antigen binding and con-
tribute to affinity. Together, these data highlight a physiological
role for Fab glycosylation as an additional mechanism of di-
versification of the antibody repertoire that modulates antigen
binding, subject to selection mechanisms to optimize the anti-
body response. Indeed, we show high levels of Fab glycosylation
for several antigen-specific immune responses, and we obtained
evidence for positive selection via antigen binding for multiple
naturally occurring antigen-specific antibody clones.
In contrast to a positive contribution to antigen binding, we
show that the level of Fab glycosylation of IgG against RhD is
quite low (i.e., lower than that of total IgG), suggesting that Fab
glycans would strongly negatively influence binding. As the ex-
tracellular loops of RhD are close to the negatively charged
plasma membrane of red blood cells, binding by antibodies
carrying (negatively charged) sialylated Fab glycans may explain
the apparent negative selection for the introduction of these
glycans. Similarly, whereas the effects of Fab glycosylation on
antigen binding found for naturally occurring antibodies are
mainly positive, probably as a result of subsequent rounds of
proliferation and selection in vivo, introducing Fab glycans bypass-
ing this selection is expected to predominantly have negative or no
effects, which is in line with our findings for the glycovariants of
adalimumab we generated, and also consistent with similar findings
for introducing follicular lymphoma-associated Fab glycans into
anti-NIP and anti-HEL mouse monoclonal antibodies (37). Also,
introducing glycans in the CDR3 of the heavy chain might more
often be disruptive for antigen binding compared with the other
loops because of steric constraints, in line with the relative absence
of sites in this region.
Nevertheless, Fab glycans were found to leave antigen binding
unaffected in more than one case, suggesting it is possible that
Fab glycans may also accumulate in part as a neutral byproduct
during SHM. However, despite a correlation between the num-
ber of mutations and the frequency of glycosylation sites, which is
expected, it is unlikely that this fully accounts for the large dif-
ferences in Fab glycosylation between various affinity-matured,
antigen-specific antibody repertoires. Alternatively, positive se-
lection of B cells carrying BCRs with Fab glycans may also in-
volve (endogenous) lectins. In this respect, it is interesting to
note that follicular lymphoma B cells may carry BCRs that are
heavily Fab glycosylated (11), and it has been suggested that lec-
tins bind to the high mannose glycans on these BCRs, and thereby
stimulate B cells (12, 37–39). Whether this mechanism of selection
also occurs for the more common highly sialylated complex bian-
tennary Fab glycans is unknown.
Enhanced Fab glycosylation was found for follicular lymphoma B
cells (11), but was also associated with RA (8) and primary Sjög-
ren’s syndrome (9). The role of Fab glycosylation in pathogenesis
has not been established. However, we confirmed the recently
reported high degree of Fab glycosylation of ACPAs, autoanti-
bodies present in the majority of patients with RA (32). Because
ACPAs are a diagnostic and prognostic biomarker in RA, further
research on the possible association between Fab glycosylation of
ACPAs and severity of the disease may provide more mechanistic
insight into the role of ACPAs in RA, such as the role of antigens
(citrullinated proteins) in provoking and/or sustaining these re-
sponses, and might help to improve diagnosis and prognosis.
Fab glycosylation of IgG4 was found to be increased compared
with that of the other IgG subclasses, even after accounting for
Fab-arm exchange. This might in part be explained by a slightly
higher mutation rate in IgG4 than in the other subclasses (40),
although overall, mutation rates and Fab glycosylation across
subclasses correlate poorly, if at all (Fig. 2B and SI Appendix, Fig.
S14). IgG4 is considered a more matured response, associated
with prolonged/repeated antigen exposure and a TH2/TREG-like
T-cell phenotype (41), which might also affect clonal selection.
The question arises whether the relative enrichment of Fab
glycosylation of IgG4 has consequences for the function of IgG4.
IgG4 antibody responses are associated with tolerance, as they
are poor activators of effector functions because of weak C1q/FcγR
binding, and their inability to form large immune complexes be-
cause of Fab-arm exchange (41). Interestingly, Fab glycans have
also been associated with immunomodulation of IVIg, of which the
sialylated fraction is highly enriched in Fab glycans and may con-
tribute to the immunomodulatory effects of IVIg treatment (7, 14).
Analogously, increased Fab glycosylation of IgG4 antibodies might
be another feature that contributes to the tolerogenic phenotype of
this particular IgG subclass. A limitation of the current study is that
the glycosylation profiles of the recombinant antibodies, although
generally high in sialic acid content, may not be entirely repre-
sentative of the in vivo profiles (Materials and Methods).
The present study also indicates that next to enhancing antigen
binding, Fab glycans may also modulate the specificity of an an-
tibody by eliminating unwanted secondary reactivities. Indeed, in
our model system of anti-idiotype antibodies with highly similar,
but not identical, binding characteristics serving as surrogate
antigens, we demonstrated substantial differential effects of Fab
A B C
D E
Fig. 4. Naturally selected Fab glycans can enhance antigen binding. (A and
B) Gel electrophoresis and lectin ELISA data for (A) anti-adalimumab clones
1.3, 2.2, and 2.6 and (B) anti-infliximab clones 1.3, 1.4, 2.1, and 2.3 (notation
as in Fig. 1F), these clones expressed in the presence of tunicamycin (tm), and
mutants (m) thereof lacking the Fab glycosylation site (experiments as in Fig.
1G). Shown are representative data of two replicates. (C) Setup of the bio-
sensor (SPR) experiments. (D and E) Using surface plasmon resonance,
(D) adalimumab (ADL) or (E) infliximab (IFX) binding affinity of the anti-ADL/
IFX clones and mutants was determined. Shown are means of at least four
replicates with SEM. For anti-ADL clone 2.2, the ka instead of the KA was
analyzed because the kd was too low to be measured (42). One-way ANOVA,
legend as in Fig. 2.





















glycans on the binding to these surrogate antigens. This illustrates
the potential for enhancing antibody selectivity by acquiring Fab
glycans that would negatively affect off-target binding rather than
enhancing on-target binding. Indeed, a recent study suggested that
Fab glycosylation may provide a mechanism to prevent autoreactivity
(15). ACPAs, RA-associated autoantibodies, were found to be
highly Fab glycosylated, possibly as a strategy of the immune
system to prevent autoreactivity, although it was also shown that
Fab glycans on ACPAs did not always negatively affect binding to
citrullinated peptides (32). In addition, patients with primary
Sjögren’s syndrome, an autoimmune disease, show increased lev-
els of Fab glycosylation, and there is little evidence for positive
(auto)antigen selection (9). It remains to be investigated how
antibodies with increased specificity would be selected.
In conclusion, we provide evidence that the introduction of
glycans in the variable domains is an inherent, additional layer of
diversification of the antibody repertoire, dependent on SHM and
subject to selection mechanisms to optimize the antibody response.
Materials and Methods
Blood samples were obtained on written informed consent with approval
from local ethics committees of the Academic Medical Centre, Amsterdam;
Reade, Amsterdam; Leiden University Medical Center, and Erasmus Medical
Center, Rotterdam, The Netherlands, as detailed in SI Appendix, SI Materials
and Methods. B-cell repertoires were analyzed by next-generation se-
quencing. For analysis of germline variable domain sequences, datasets of
rearranged variable domain sequences, and analysis of rearranged variable
domain sequences, see SI Appendix, SI Materials and Methods. Multiple
human polyclonal and monoclonal (auto)antibodies were analyzed for levels
of variable domain glycosylation. For samples, lectin (SNA) affinity chro-
matography, total and specific IgG immunoassays, monoclonal antigen-
specific antibodies, and analysis of glycosylation site occupancy, see SI Ap-
pendix, SI Materials and Methods. Effects on binding were evaluated by
recombinantly removing or introducing N-glycosylation sites. Details on
antibody glycovariants, gel electrophoresis, surface plasmon resonance
measurements, and MALDI-TOF-MS N-linked glycan analysis given in SI Ap-
pendix, SI Materials and Methods.
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